Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection.

Marcellin P, Wong DK, Sievert W, Buggisch P, Petersen J, Flisiak R, Manns M, Kaita K, Krastev Z, Lee SS, Cathcart AL, Crans G, Op den Brouw M, Jump B, Gaggar A, Flaherty J, Buti M.

Liver Int. 2019 May 28. doi: 10.1111/liv.14155. [Epub ahead of print]

PMID:
31136052
2.

No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection.

Cathcart AL, Chan HL, Bhardwaj N, Liu Y, Marcellin P, Pan CQ, Shalimar, Buti M, Cox S, Parhy B, Zhou E, Martin R, Chang S, Lin L, Flaherty JF, Kitrinos KM, Gaggar A, Izumi N, Lim YS.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e01064-18. doi: 10.1128/AAC.01064-18. Print 2018 Oct.

3.

Safety and efficacy of vesatolimod (GS-9620) in patients with chronic hepatitis B who are not currently on antiviral treatment.

Agarwal K, Ahn SH, Elkhashab M, Lau AH, Gaggar A, Bulusu A, Tian X, Cathcart AL, Woo J, Subramanian GM, Andreone P, Kim HJ, Chuang WL, Nguyen MH.

J Viral Hepat. 2018 Nov;25(11):1331-1340. doi: 10.1111/jvh.12942. Epub 2018 Aug 22.

PMID:
29851204
4.

96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection.

Agarwal K, Brunetto M, Seto WK, Lim YS, Fung S, Marcellin P, Ahn SH, Izumi N, Chuang WL, Bae H, Sharma M, Janssen HLA, Pan CQ, Çelen MK, Furusyo N, Shalimar D, Yoon KT, Trinh H, Flaherty JF, Gaggar A, Lau AH, Cathcart AL, Lin L, Bhardwaj N, Suri V, Mani Subramanian G, Gane EJ, Buti M, Chan HLY; GS-US-320-0110; GS-US-320-0108 Investigators.

J Hepatol. 2018 Apr;68(4):672-681. doi: 10.1016/j.jhep.2017.11.039. Epub 2018 Jan 17.

PMID:
29756595
5.

Development of a digital droplet PCR assay to measure HBV DNA in patients receiving long-term TDF treatment.

Liu Y, Cathcart AL, Delaney WE 4th, Kitrinos KM.

J Virol Methods. 2017 Nov;249:189-193. doi: 10.1016/j.jviromet.2017.09.015. Epub 2017 Sep 18.

PMID:
28923315
6.

Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial.

Buti M, Gane E, Seto WK, Chan HL, Chuang WL, Stepanova T, Hui AJ, Lim YS, Mehta R, Janssen HL, Acharya SK, Flaherty JF, Massetto B, Cathcart AL, Kim K, Gaggar A, Subramanian GM, McHutchison JG, Pan CQ, Brunetto M, Izumi N, Marcellin P; GS-US-320-0108 Investigators.

Lancet Gastroenterol Hepatol. 2016 Nov;1(3):196-206. doi: 10.1016/S2468-1253(16)30107-8. Epub 2016 Sep 22. Erratum in: Lancet Gastroenterol Hepatol. 2016 Nov;1(3):e2.

PMID:
28404092
7.

No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment.

Liu Y, Corsa AC, Buti M, Cathcart AL, Flaherty JF, Miller MD, Kitrinos KM, Marcellin P, Gane EJ.

J Viral Hepat. 2017 Jan;24(1):68-74. doi: 10.1111/jvh.12613. Epub 2016 Sep 23.

PMID:
27658343
8.

Generation of Recombinant Polioviruses Harboring RNA Affinity Tags in the 5' and 3' Noncoding Regions of Genomic RNAs.

Flather D, Cathcart AL, Cruz C, Baggs E, Ngo T, Gershon PD, Semler BL.

Viruses. 2016 Feb 4;8(2). pii: E39. doi: 10.3390/v8020039.

9.

An Intranasal Virus-Like Particle Vaccine Broadly Protects Mice from Multiple Subtypes of Influenza A Virus.

Schwartzman LM, Cathcart AL, Pujanauski LM, Qi L, Kash JC, Taubenberger JK.

MBio. 2015 Jul 21;6(4):e01044. doi: 10.1128/mBio.01044-15.

10.

Differential restriction patterns of mRNA decay factor AUF1 during picornavirus infections.

Cathcart AL, Semler BL.

J Gen Virol. 2014 Jul;95(Pt 7):1488-92. doi: 10.1099/vir.0.064501-0. Epub 2014 Apr 10.

11.

Cellular mRNA decay protein AUF1 negatively regulates enterovirus and human rhinovirus infections.

Cathcart AL, Rozovics JM, Semler BL.

J Virol. 2013 Oct;87(19):10423-34. doi: 10.1128/JVI.01049-13. Epub 2013 Jul 31.

12.

Viral proteinase requirements for the nucleocytoplasmic relocalization of cellular splicing factor SRp20 during picornavirus infections.

Fitzgerald KD, Chase AJ, Cathcart AL, Tran GP, Semler BL.

J Virol. 2013 Mar;87(5):2390-400. doi: 10.1128/JVI.02396-12. Epub 2012 Dec 19.

13.

Picornavirus modification of a host mRNA decay protein.

Rozovics JM, Chase AJ, Cathcart AL, Chou W, Gershon PD, Palusa S, Wilusz J, Semler BL.

MBio. 2012 Nov 6;3(6):e00431-12. doi: 10.1128/mBio.00431-12.

Supplemental Content

Loading ...
Support Center